氯卡色林、芬特明-托吡酯组合及纳曲酮-安非他酮组合用于减肥：区分这些药物的15分钟挑战 - Suppr

Suppr

超能文献

Lorcaserin, phentermine topiramate combination, and naltrexone bupropion combination for weight loss: the 15-min challenge to sort these agents out.

作者信息

Citrome L

机构信息

New York Medical College, Valhalla, NY, USA.

出版信息

Int J Clin Pract. 2014 Dec;68(12):1401-5. doi: 10.1111/ijcp.12587.

DOI:10.1111/ijcp.12587

PMID:25418525

Abstract

摘要

相似文献

Lorcaserin, phentermine topiramate combination, and naltrexone bupropion combination for weight loss: the 15-min challenge to sort these agents out.

Int J Clin Pract. 2014 Dec;68(12):1401-5. doi: 10.1111/ijcp.12587.

Overview of new antiobesity drugs.

Expert Opin Pharmacother. 2014 Oct;15(14):1975-8. doi: 10.1517/14656566.2014.946904. Epub 2014 Aug 6.

Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.

JAMA. 2016 Jun 14;315(22):2424-34. doi: 10.1001/jama.2016.7602.

Drug treatment of obesity: current status and future prospects.

Eur J Intern Med. 2015 Mar;26(2):89-94. doi: 10.1016/j.ejim.2015.01.005. Epub 2015 Jan 26.

Nonincretin drugs in later-stage development.

Am J Manag Care. 2014 Jan;20(1 Spec No.):E2.

Obesity Pharmacotherapy.

Med Clin North Am. 2018 Jan;102(1):135-148. doi: 10.1016/j.mcna.2017.08.010.

A Comparison of New Pharmacological Agents for the Treatment of Obesity.

Ann Pharmacother. 2016 May;50(5):376-88. doi: 10.1177/1060028016634351. Epub 2016 Feb 17.

Obesity Epidemic: Pharmaceutical Weight Loss.

R I Med J (2013). 2017 Mar 1;100(2):18-20.

Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release.

Expert Opin Drug Saf. 2017 Jan;16(1):27-39. doi: 10.1080/14740338.2017.1247807. Epub 2016 Oct 24.

Current and emerging pharmacotherapies for obesity in Australia.

Obes Res Clin Pract. 2017 Sep-Oct;11(5):501-521. doi: 10.1016/j.orcp.2017.07.002. Epub 2017 Aug 14.

引用本文的文献

Naltrexone + Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study.

Clin Ther. 2021 Jan;43(1):112-122.e1. doi: 10.1016/j.clinthera.2020.10.010. Epub 2020 Nov 18.

Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity.

Drugs. 2019 Feb;79(3):219-230. doi: 10.1007/s40265-019-1057-0.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Lorcaserin, phentermine topiramate combination, and naltrexone bupropion combination for weight loss: the 15-min challenge to sort these agents out.

Int J Clin Pract. 2014 Dec;68(12):1401-5. doi: 10.1111/ijcp.12587.

Overview of new antiobesity drugs.

Expert Opin Pharmacother. 2014 Oct;15(14):1975-8. doi: 10.1517/14656566.2014.946904. Epub 2014 Aug 6.

Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.

JAMA. 2016 Jun 14;315(22):2424-34. doi: 10.1001/jama.2016.7602.

Drug treatment of obesity: current status and future prospects.

Eur J Intern Med. 2015 Mar;26(2):89-94. doi: 10.1016/j.ejim.2015.01.005. Epub 2015 Jan 26.

Nonincretin drugs in later-stage development.

Am J Manag Care. 2014 Jan;20(1 Spec No.):E2.

Obesity Pharmacotherapy.

Med Clin North Am. 2018 Jan;102(1):135-148. doi: 10.1016/j.mcna.2017.08.010.

A Comparison of New Pharmacological Agents for the Treatment of Obesity.

Ann Pharmacother. 2016 May;50(5):376-88. doi: 10.1177/1060028016634351. Epub 2016 Feb 17.

Obesity Epidemic: Pharmaceutical Weight Loss.

R I Med J (2013). 2017 Mar 1;100(2):18-20.

Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release.

Expert Opin Drug Saf. 2017 Jan;16(1):27-39. doi: 10.1080/14740338.2017.1247807. Epub 2016 Oct 24.

Current and emerging pharmacotherapies for obesity in Australia.

Obes Res Clin Pract. 2017 Sep-Oct;11(5):501-521. doi: 10.1016/j.orcp.2017.07.002. Epub 2017 Aug 14.

引用本文的文献

Naltrexone + Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study.

Clin Ther. 2021 Jan;43(1):112-122.e1. doi: 10.1016/j.clinthera.2020.10.010. Epub 2020 Nov 18.

Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity.

Drugs. 2019 Feb;79(3):219-230. doi: 10.1007/s40265-019-1057-0.